← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Aradhana Sarin
Ekonomichef/finanschef/finansdirektör
Profile key: se|aradhana sarin
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 3
- Average purchase
- £0
- Gross purchase value
- £0
- Last purchase
- 2026-09-14
- Completed 20D events
- 3.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: AstraZeneca PLC
Companies: AstraZeneca PLC
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -0.2% | -0.1% | -1.0% |
| 20D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +1.7% | +1.2% | -3.6% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -7.0% | -7.0% | -7.0% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -24.2% | -24.2% | -24.2% |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ €100k
- Not classifiable
- Cluster buying · 15D
- 2/3
- Buying the dip · ≥20% below prior 52W high
- 2/3
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.